StoxCaplin Point Laboratories vs Cohance Lifesciences: share price & financials comparison
NSE: CAPLIPOINT vs COHANCE · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Caplin Point Laboratories vs Cohance Lifesciences at a glance
Caplin Point Laboratories (CAPLIPOINT) has a market capitalisation of ₹18,107 Cr, against ₹16,588 Cr for Cohance Lifesciences (COHANCE). Over the past year Caplin Point Laboratories has returned +17.9%, compared with -44.9% for Cohance Lifesciences. On valuation, Caplin Point Laboratories trades at a lower P/E of 27.2 versus 156.1. Caplin Point Laboratories earns a higher return on equity (18.6% vs 2.7%). Caplin Point Laboratories comes out ahead on size, profitability, growth, financial health, momentum and technicals. Across the scored metrics below, Caplin Point Laboratories leads on 13 and Cohance Lifesciences on 3. On StoxGud's 10-point checklist, Caplin Point Laboratories scores 9/10 and Cohance Lifesciences scores 3/10.
| Metric | Caplin Point Laboratories | Cohance Lifesciences |
|---|---|---|
| Size | ||
| Market cap | ₹18,107 Cr | ₹16,588 Cr |
| Revenue (latest FY) | ₹2,187 Cr | ₹2,269 Cr |
| Net profit (latest FY) | ₹641 Cr | ₹179 Cr |
| Valuation | ||
| P/E | 27.2 | 156.1 |
| P/B | 5.05 | 4.24 |
| Dividend yield | 0.25% | — |
| Profitability | ||
| Return on equity | 18.6% | 2.7% |
| Net profit margin | 29.1% | 5.0% |
| Operating margin | 34.8% | 14.8% |
| Growth | ||
| Revenue growth (YoY) | +19.6% | -23.1% |
| Net profit growth (YoY) | +15.8% | -149.3% |
| Revenue CAGR (multi-year) | +15.6% | +18.2% |
| Financial health | ||
| Debt to equity | 0.00 | 0.04 |
| Momentum | ||
| 1-month return | -10.1% | -4.8% |
| 1-year return | +17.9% | -44.9% |
| 3-year CAGR | +29.7% | -8.8% |
| 5-year CAGR | +22.9% | -2.9% |
| 10-year CAGR | +20.1% | — |
| Distance from 52W high | -16.9% | -44.3% |
| Technicals | ||
| RSI (14) | 59 | 39 |
| Price vs 200-day avg | +9.5% | +5.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Caplin Point Laboratories | Cohance Lifesciences |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✓ | ✗ |
| Score | 9/10 | 3/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Caplin Point Laboratories or Cohance Lifesciences?
Caplin Point Laboratories has a market cap of ₹18,107 Cr and Cohance Lifesciences has a market cap of ₹16,588 Cr as of 06 Nov 2026.
Which has a lower P/E, Caplin Point Laboratories or Cohance Lifesciences?
Caplin Point Laboratories has the lower P/E: Caplin Point Laboratories trades at 27.2 and Cohance Lifesciences at 156.1.
Which gave better returns in the last year, Caplin Point Laboratories or Cohance Lifesciences?
Caplin Point Laboratories did better: Caplin Point Laboratories returned +17.9% and Cohance Lifesciences returned -44.9% over one year.
Is Caplin Point Laboratories or Cohance Lifesciences a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Caplin Point Laboratories scores 9/10 and Cohance Lifesciences scores 3/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.